Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenylether SCHEMBL9186513 | 0.90 | MEN1 (0.41) | RIPK1TAAR1AOC3KDM4EMEN1 | |
| SCHEMBL17627638 | 0.81 | RIPK1 (0.65) | RIPK1TAAR1AOC3TRPA1KDM4E | |
| SCHEMBL10195095 | 0.80 | RIPK1 (0.44) | RIPK1TAAR1AOC3TRPA1KDM4E | |
| SCHEMBL30203833 | 0.79 | CTSS (0.35) | RIPK1TRPA1KDM4EMEN1HTT | |
| SCHEMBL28133086 | 0.78 | RIPK1 (0.53) | RIPK1TAAR1AOC3TRPA1KDM4E | |
| SCHEMBL5664123 | 0.77 | RIPK1 (0.63) | RIPK1TAAR1AOC3TRPA1CACNA1F | |
| SCHEMBL21322418 | 0.74 | TAAR1 (0.56) | RIPK1TAAR1AOC3TRPA1KDM4E | |
| SCHEMBL20427677 | 0.74 | RIPK1 (0.53) | RIPK1TAAR1AOC3TRPA1KDM4E | |
| SCHEMBL2418232 | 0.74 | RIPK1 (0.53) | RIPK1TAAR1AOC3TRPA1CACNA1F | |
| SCHEMBL17123623 | 0.73 | RIPK1 (0.41) | RIPK1TAAR1TRPA1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655373-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2025-12-03 | — | — | EP | claimed |
| WO-2024156688-A1 | BIODEGRADABLE PERFUME COMPOSITION | GIVAUDAN SA (CH) | 2024-08-02 | — | — | WO | claimed |
| EP-4407019-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2024-07-31 | — | — | EP | claimed |
| EP-2555742-B2 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2018-12-05 | — | — | EP | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| EP-2556139-B1 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2017-08-02 | — | — | EP | claimed |
| EP-2555742-B1 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2016-03-16 | — | — | EP | claimed |
| US-9023783-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2015-05-05 | — | — | US | claimed |
| US-20140342969-A1 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2014-11-20 | — | — | US | claimed |
| US-8822402-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2014-09-02 | — | — | US | claimed |
| US-8633148-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2014-01-21 | — | — | US | claimed |
| EP-2556139-A1 | ENCAPSULATES | The Procter & Gamble Company (US) | 2013-02-13 | — | — | EP | claimed |
| EP-2555742-A1 | ENCAPSULATES | The Procter & Gamble Company (US) | 2013-02-13 | — | — | EP | claimed |
| WO-2011127011-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2011-10-13 | — | — | WO | claimed |
| WO-2011127030-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2011-10-13 | — | — | WO | claimed |
| US-20110245134-A1 | ENCAPSULATES | PROCTER & GAMBLE COMPANY, THE | 2011-10-06 | — | — | US | claimed |
| US-20110245136-A1 | ENCAPSULATES | PROCTER & GAMBLE COMPANY, THE | 2011-10-06 | — | — | US | claimed |
| US-12590264-B2 | Profragrance conjugates | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-5143899-A | Process for preparing phenyl butyronitriles and perfumery use of 2,2-dimethyl-4-phenyl valeronitrile | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1992-09-01 | — | — | US | disclosed |
| US-5143899-A | Process for preparing phenyl butyronitriles and perfumery use of 2,2-dimethyl-4-phenyl valeronitrile | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1992-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590264-B2 | Profragrance conjugates | TRPA1, TST, HSF1 | RIPK1 4277/4885TAAR1 1058/4885AOC3 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.